[1]金健,金大地.利塞膦酸钠抑制大鼠骨髓内脂肪细胞分化及脂肪细胞核因子κB受体活化因子配体蛋白的表达[J].南方医科大学学报,2019,(08):987.[doi:10.12122/j.issn.1673-4254.2019.08.17]
点击复制

利塞膦酸钠抑制大鼠骨髓内脂肪细胞分化及脂肪细胞核因子κB受体活化因子配体蛋白的表达()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2019年08期
页码:
987
栏目:
出版日期:
2019-08-31

文章信息/Info

Title:
Risedronate inhibits rat bone marrow adipogenesis and reduces RANKL expression in adipocytes
作者:
金健金大地
关键词:
利塞膦酸钠双膦酸盐脂肪细胞核因子κB受体活化因子配体骨质疏松
Keywords:
risedronate bisphosphonate adipocyte receptor activator of nuclear factor κB ligand osteoporosis
DOI:
10.12122/j.issn.1673-4254.2019.08.17
摘要:
目的研究利塞膦酸钠(RIS)对大鼠骨髓间充质干细胞成脂分化的影响及对骨髓内脂肪细胞来源的核因子κB受体活化因 子配体(RANKL)的调节作用,为阐明RIS抗骨质疏松的机制提供新的理论依据。方法大鼠骨髓间充质干细胞成脂诱导及非 成脂诱导14 d,期间以浓度梯度0、1、5、10、25 μmol/L的RIS进行药物干预,观察并计算成脂率,提取蛋白通过Western blot实验 检测RANKL蛋白表达。将24周的SD大鼠随机分成假手术组及OVX组,12周后OVX大鼠再次随机分为RIS干预组(2.4 μg/kg, 皮下注射,3次/周)及对照组。8周后行骨密度检查,并取大鼠左股骨远端骨骼标本行病理检查,观察RIS对大鼠骨髓内脂肪含 量的影响。结果体外实验发现RIS呈浓度依赖性抑制大鼠骨髓间充质干细胞向脂肪细胞分化,并且,随着RIS浓度的升高,骨 髓内脂肪细胞RANKL蛋白的表达逐渐降低(P<0.05)。体内实验发现RIS药物干预后,OVX大鼠骨密度显著提升的同时,骨髓 内脂肪的含量明显降低(P<0.05)。结论RIS可有效抑制大鼠骨髓间充质干细胞的成脂分化,降低骨髓内的脂肪含量,并通过下 调脂肪细胞RANKL的表达,抑制破骨细胞的生成和功能,这可能是RIS发挥抗骨质疏松作用的机制。
Abstract:
Objective To investigate the effects of risedronate on bone marrow adipogenesis and the expression of the receptor activator of nuclear factor κB ligand (RANKL) in adipocytes in the bone marrow micro-environment. Methods Primary cultured rat mesenchymal stem cells (BMSCs) with or without adipogenic induction for 14 days were treated with 1, 5, 10, and 25 μmol/L risedronate. The droplets of the differentiated adipocytes were analyzed, and Western blotting was performed to detect the expression level of RANKL. Female SD rats (24-week-old) were randomly divided into sham-operated group and ovariectomy (OVX) group, and 12 weeks after the operation, the OVX rats were further divided into control group and risedronate group (2.4 μg/kg, injected subcutaneously for 3 times a week). Eight weeks later, the bone mineral density (BMD) of the rats and bone marrow histopathology of the femurs was examined to evaluate the effect of risedronate on the fat fraction in the bone marrow. Results Risdronate significantly inhibited adipogenic differentiation of rat BMSCs and suppressed RANKL expression in the adipocytes derived from the BMSCs in a concentration-dependent manner. In OVX rats, risdronate treatment significantly increased the BMD and decreased the fat content in the bone marrow. Conclusion Risdronate can effectively inhibit the adipogenic differentiation of rat BMSCs, decrease fat content in the bone marrow, and suppress the generation and function of osteoclasts by down-regulating the expression of RANKL, which can be an important mechanism underlying the therapeutic effect of risedronate against osteoporosis.

相似文献/References:

[1]宋志强,董伟,阴露佳,等.沙利度胺对双膦酸盐相关颌骨坏死的影响[J].南方医科大学学报,2015,(08):1084.

更新日期/Last Update: 1900-01-01